CRISPR Therapeutics AG (CRSP) Equity Income (2018 - 2019)
CRISPR Therapeutics AG (CRSP) reported Equity Income of $22.6 million for Q3 2019, up 67.41% on a YoY basis from $13.5 million in Q3 2018, and up 24.86% sequentially from $18.1 million in Q2 2019.
CRISPR Therapeutics AG (CRSP) Equity Income (2018 - 2019) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 2 years of Equity Income data on file, last reported at $22.6 million in Q3 2019.
- For the quarter ending Q3 2019, Equity Income rose 67.41% year-over-year to $22.6 million; the trailing twelve-month figure through Sep 2019 stood at $81.6 million (changed N/A YoY), and the FY2018 full-year result was $52.5 million, up 45.03% from the prior year.
- Equity Income advanced to $22.6 million in Q3 2019, from $18.1 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of $26.7 million in Q4 2018 to a low of $13.5 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 22.60 Mn |
| Jun 30, 2019 | 18.10 Mn |
| Mar 31, 2019 | 14.20 Mn |
| Dec 31, 2018 | 26.70 Mn |
| Sep 30, 2018 | 13.50 Mn |
| Jun 30, 2018 | 13.50 Mn |